Literature DB >> 10858365

In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori.

A M Hirschl1, P Apfalter, A Makristathis, M L Rotter, M Wimmer.   

Abstract

Linezolid was tested against 70 strains of Helicobacter pylori by the agar dilution method. The MIC range and MICs at which 50 and 90% of strains were inhibited were 8 to 64, 16, and 32 microgram/ml, respectively. With minimum and maximum fractional inhibitory concentration summation values of 0.31 and 2.50, respectively, the combination of linezolid with amoxicillin, clarithromycin, or metronidazole showed either partial synergy or indifference for the majority of strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858365      PMCID: PMC89996          DOI: 10.1128/AAC.44.7.1977-1979.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.

Authors:  K McColl; L Murray; E El-Omar; A Dickson; A El-Nujumi; A Wirz; A Kelman; C Penny; R Knill-Jones; T Hilditch
Journal:  N Engl J Med       Date:  1998-12-24       Impact factor: 91.245

3.  Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

Authors:  A L Blum; N J Talley; C O'Moráin; S V van Zanten; J Labenz; M Stolte; J A Louw; A Stubberöd; A Theodórs; M Sundin; E Bolling-Sternevald; O Junghard
Journal:  N Engl J Med       Date:  1998-12-24       Impact factor: 91.245

Review 4.  Gastric diffusion of antibiotics used against Helicobacter pylori.

Authors:  A Lozniewski; J D de Korwin; F Muhale; F Jehl
Journal:  Int J Antimicrob Agents       Date:  1997-01       Impact factor: 5.283

5.  Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Authors:  F Mégraud; N Lehn; T Lind; E Bayerdörffer; C O'Morain; R Spiller; P Unge; S V van Zanten; M Wrangstadh; C F Burman
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.

Authors:  G A Noskin; F Siddiqui; V Stosor; D Hacek; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

7.  In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.

Authors:  J H Jorgensen; M L McElmeel; C W Trippy
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 8.  Antibiotic resistance in Helicobacter pylori: implications for therapy.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1998-11       Impact factor: 22.682

9.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.

Authors:  R N Jones; D M Johnson; M E Erwin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more
  4 in total

1.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors.

Authors:  Jed W Fahey; Xavier Haristoy; Patrick M Dolan; Thomas W Kensler; Isabelle Scholtus; Katherine K Stephenson; Paul Talalay; Alain Lozniewski
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole.

Authors:  A Blacky; A Makristathis; P Apfalter; B Willinger; M L Rotter; A M Hirschl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-04       Impact factor: 3.267

4.  In Vitro Activity of Sertraline, an Antidepressant, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains.

Authors:  Paweł Krzyżek; Roman Franiczek; Barbara Krzyżanowska; Łukasz Łaczmański; Paweł Migdał; Grażyna Gościniak
Journal:  Pathogens       Date:  2019-11-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.